Coherus BioSciences Total Assets 2013-2021 | CHRS

Coherus BioSciences total assets from 2013 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Coherus BioSciences Annual Total Assets
(Millions of US $)
2020 $842
2019 $409
2018 $99
2017 $163
2016 $178
2015 $212
2014 $187
2013 $47
2012 $27
2011 $1,018
2010 $1,023
2009 $1,157
2008 $1,277
2007 $1,613
2006 $1,706
2005 $1,573
Coherus BioSciences Quarterly Total Assets
(Millions of US $)
2021-09-30 $742
2021-06-30 $740
2021-03-31 $693
2020-12-31 $842
2020-09-30 $804
2020-06-30 $757
2020-03-31 $467
2019-12-31 $409
2019-09-30 $327
2019-06-30 $240
2019-03-31 $186
2018-12-31 $99
2018-09-30 $141
2018-06-30 $188
2018-03-31 $128
2017-12-31 $163
2017-09-30 $190
2017-06-30 $172
2017-03-31 $227
2016-12-31 $178
2016-09-30 $192
2016-06-30 $251
2016-03-31 $226
2015-12-31 $212
2015-09-30 $202
2015-06-30 $250
2015-03-31 $153
2014-12-31 $187
2014-09-30 $129
2014-06-30 $0
2014-03-31 $0
2013-12-31 $0
2013-09-30 $47
2012-12-31 $27
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.363B $0.476B
Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90